UPDATE | February 13, 2023

Samsung Biologics awarded Management status by CDP for climate change impact

  • MAIL

Samsung Biologics awarded Management status by CDP for climate change impact
 

Samsung Biologics has been recognized by the Carbon Disclosure Project (CDP) for the company’s ongoing environmental management. As part of its annual ratings, the CDP granted Samsung Biologics a B rating in 2022, equivalent to ‘Management’ status, for its committed actions and transparent disclosures on climate change.

 

As a global nonprofit, the CDP’s annual environmental disclosure and scoring process is considered a standard of corporate environmental transparency. More than 18,700 companies worldwide are assessed every year over eleven categories including risk assessment and opportunities, targets and goals, governance, strategy and mitigation efforts, and response performance. 

Samsung Biologics has taken another step forward to building a sustainable future and enhancing its ESG governance. The company is utilizing low-carbon technologies, such as ultra-low NOx burner and Solar panel, to help low greenhouse gases its operations, and a larger amount of renewable energy are expected to be introduced for use across plants. The company also recently published its first Task Force on Climate-Related Financial Disclosures (TCFD) report as well as joined RE100 with a target of reaching net zero across all operations by 2050 or earlier.

Samsung Biologics awarded Management status by CDP for climate change impact
 

Samsung Biologics has been recognized by the Carbon Disclosure Project (CDP) for the company’s ongoing environmental management. As part of its annual ratings, the CDP granted Samsung Biologics a B rating in 2022, equivalent to ‘Management’ status, for its committed actions and transparent disclosures on climate change.

 

As a global nonprofit, the CDP’s annual environmental disclosure and scoring process is considered a standard of corporate environmental transparency. More than 18,700 companies worldwide are assessed every year over eleven categories including risk assessment and opportunities, targets and goals, governance, strategy and mitigation efforts, and response performance. 

Samsung Biologics has taken another step forward to building a sustainable future and enhancing its ESG governance. The company is utilizing low-carbon technologies, such as ultra-low NOx burner and Solar panel, to help low greenhouse gases its operations, and a larger amount of renewable energy are expected to be introduced for use across plants. The company also recently published its first Task Force on Climate-Related Financial Disclosures (TCFD) report as well as joined RE100 with a target of reaching net zero across all operations by 2050 or earlier.

  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

  • MAIL

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required